Metabolic inhibition and kinetics of raloxifene by pharmaceutical excipients in human liver microsomes

International Journal of Pharmaceutics

Volumn 368, Issue 1-2, 2009, Pages 37-44

  Kim, Ae Ra ^a   Lim, Soo Jeong ^b   Lee, Beom Jin ^a  

^a Kangwon National University   (South Korea)

^b Sejong University   (South Korea)

Author keywords

Inhibition of hepatic metabolism; Metabolic factors; Metabolic kinetics; Pharmaceutical excipients; Raloxifene

Indexed keywords

CREMOPHOR; DODECYL SULFATE SODIUM; GELUCIRE; MACROGOL 6000; POLIDOCANOL; POLOXAMER; POLYOXYETHYLENE OLEYL ETHER; POLYSORBATE 80; POVIDONE DERIVATIVE; RALOXIFENE; TWEEN; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG STABILITY; EXCIPIENT COMPATIBILITY; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; METABOLIC INHIBITION; PRIORITY JOURNAL;

BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCIPIENTS; HUMANS; KINETICS; MASS SPECTROMETRY; MICROSOMES, LIVER; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 58949099347     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.09.049     Document Type: Article

References (30)

1. Azmin M.N., Florence A.T., Handjani-Vila R.M., Stuart J.F., Vanlerberghe G., and Whittaker J.S. The effect of niosomes and polysorbate 80 on the metabolism and excretion of methotrexate in the mouse. J. Microencapsul. 3 (1986) 95-100
2. Bourrié M., Meunier V., Berger Y., and Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277 (1996) 321-332
3. Bravo Gonzalez R.C., Huwyler J., Boess F., Walter I., and Bittner B. In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam. Biopharm. Drug Dispos. 25 (2004) 37-49
4. Close P., Neuprez A., and Reginster J.Y. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin. Pharmacother. 7 (2006) 1603-1615
5. Cornaire G., Woodley J., Hermann P., Cloarec A., Arellano C., and Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 278 (2004) 119-131
6. da Silva M.E., and Meirelles N.C. Interaction of non-ionic surfactants with hepatic CYP in Prochilodus scrofa. Toxicol. In vitro 18 (2004) 859-867
7. Green M.D., and Tephly T.R. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1. 4 protein. Drug Metab. Dispos. 24 (1996) 356-363
8. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur. J. Obstet. Gynecol. Reprod. Biol. 85 (1999) 23-29
9. Illing H.P., and House E.S. Effects of detergents and organic solvents on rat liver microsomal UDP-glucuronosyltransferase activity towards phenolic substrates. Xenobiotic 11 (1981) 709-718
10. Izutsu K., and Kojima S. Excipient crystallinity and its protein-structure-stabilizing effect during freeze-drying. J. Pharm. Pharmacol. 54 (2002) 1033-1039
11. Jeong E.J., Lin H., and Hu M. Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J. Pharmacol. Exp. Ther. 310 (2004) 376-385
12. Johnson B.M., Charman W.N., and Porter C.J. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 4 (2002) E40
13. i in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab. Dispos. 27 (1999) 756-762
14. Kemp D.C., Fan P.W., and Stevens J.C. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab. Dispos. 30 (2002) 694-700
15. Kurkela M., García-Horsman J.A., Luukkanen L., Mörsky S., Taskinen J., Baumann M., Kostiainen R., Hirvonen J., and Finel M. Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J. Biol. Chem. 278 (2003) 3536-3544
16. Lindstrom T.D., Whitaker N.G., and Whitaker G.W. Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica 14 (1984) 841-847
17. Meech R., and Mackenzie P.I. Structure and function of uridine diphosphate glucuronosyltransferases. Clin. Exp. Pharmacol. Physiol. 24 (1997) 907-915
18. Morello K.C., Wurz G.T., and DeGregorio M.W. Pharmacokinetics of selective estrogen receptor modulators. Clin. Pharmacokinet. 42 (2003) 361-372
19. Ren S., Park M.-J., Sah H., and Lee B.-J. Effect of pharmaceutical excipients upon aqueous stability of rabeprazole sodium. Int. J. Pharm. 350 (2008) 197-204
20. Ren S., Park M.-J., Kim A., and Lee B.-J. In vitro metabolic stability of moisture-sensitive rabeprazole in human liver microsomes and its modulation by pharmaceutical excipients. Arch. Pharm. Res. 31 (2008) 406-413
21. Thanou M., Verhoef J.C., and Junginger H.E. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 50 (2001) S91-101
22. Thomassin J., Boutin J.A., and Siest G. UDP-glucuronosyltransferase(s) activities towards natural substrates in rat liver microsomes. Kinetic properties and influence of triton X-100 activation. Pharmacol. Res. Commun. 17 (1985) 1005-1015
23. Tian F., Sandler N., Aaltonen J., Lang C., Saville D.J., Gordon K.C., Strachan C.J., Rantanen J., and Rades T. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts. J. Pharm. Sci. 96 (2006) 584-594
24. Tirucherai G.S., and Mitra A.K. Effect of hydroxypropyl beta-cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. AAPS PharmSciTech 4 (2003) E45
25. Trapnell C.B., Klecker R.W., Jamis-Dow C., and Collins J.M. Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob. Agents Chemother. 42 (1998) 1592-1596
26. Tukey R.H., and Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 581-616
27. Ubeaud G., Hagenbach J., Vandenschrieck S., Jung L., and Koffel J.C. In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Life Sci. 65 (1999) 1403-1412
28. Villalobos-Hernandez J.R., and Villafuerte-Robles L. Effect of carrier excipient and processing on stability of indorenate hydrochloride/excipient mixtures. Pharm. Dev. Technol. 6 (2001) 551-561
29. Watkins P.B. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol. Clin. North Am. 21 (1992) 511-526
30. Zamek-Gliszczynski M.J., Hoffmaster K.A., Nezasa K., Tallman M.N., and Brouwer K.L. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci. 27 (2006) 447-486